As of January 22, 2025, HilleVax (HLVX) has a market cap of $94.632 million USD. According to our data, HilleVax is ranked No.7730 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $94.63 M |
-8.21%
|
Dec 31, 2024 | $0.10 B |
-87.10%
|
Dec 29, 2023 | $0.80 B |
-4.06%
|
Dec 30, 2022 | $0.83 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Pfizer
PFE
|
$147.40 B |
-0.003 M
|
USA
|
GlaxoSmithKline
GSK
|
$68.21 B |
-0.002 M
|
UK
|
Merck
MRK
|
$242.04 B |
-0.000 M
|
USA
|
Johnson & Johnson
JNJ
|
$349.75 B |
0.001 M
|
USA
|
Sanofi
SNY
|
$129.14 B |
0.001 M
|
France
|
AstraZeneca
AZN
|
$211.49 B |
0.007 M
|
UK
|
Moderna
MRNA
|
$14.82 B |
-0.000 M
|
USA
|
Novavax
NVAX
|
$1.41 B |
-0.000 M
|
USA
|
BioNTech
BNTX
|
$27.61 B |
0.000 M
|
Germany
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
Amgen
AMGN
|
$146.98 B |
0.004 M
|
USA
|
Eli Lilly
LLY
|
$678.07 B |
0.022 M
|
USA
|
Market Cap | = | HLVX Stock Price | * | HLVX Shares Outstanding |
= | $1.90 | * | 49.81 M | |
= | $94.63 M |